<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">34954745</PMID>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1935-3227</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of addiction medicine</Title>
          <ISOAbbreviation>J Addict Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Oxazepam Detected in Urine 79 Days After Withdrawal of Diazepam: A Case Report.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/ADM.0000000000000944</ELocationID>
        <Abstract>
          <AbstractText>Patients suffering from substance use disorder, including for instance benzodiazepines, may have comorbidity with attention deficit hyperactivity disorder (ADHD). Centrally acting stimulants play an important role in the treatment of ADHD. Before such treatment can be initiated, withdrawal of benzodiazepines may be necessary. Urine testing is the preferred method for monitoring adherence in benzodiazepine withdrawal, but there is a lack of studies reporting detection time. Here, we report a case of a 30-year-old woman with substance use disorder and ADHD who had detectable metabolites of diazepam 79 days after withdrawal. To our knowledge, no cases with detection time equivalent to this have previously been published. This case report serves as an example that clinicians may need to consider interindividual pharmacokinetic characteristics when interpreting the results of urine drug tests, and that a positive urine test may still be consistent with abstinence from a certain drug. In the current case, a high body mass index and a genetic polymorphism gave a reasonable explanation for the prolonged detection of diazepam metabolites.</AbstractText>
          <CopyrightInformation>Copyright © 2021 American Society of Addiction Medicine.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Serkland</LastName>
            <ForeName>Trond Trætteberg</ForeName>
            <Initials>TT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway (TTS, GHD, JAB, CBM); University of Bergen, Bergen, Norway (TTS, JAB); Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway (ICK).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dale</LastName>
            <ForeName>Gro Helen</ForeName>
            <Initials>GH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaldestad</LastName>
            <ForeName>Ingeborg Caroline</ForeName>
            <Initials>IC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Berg</LastName>
            <ForeName>Jon Andsnes</ForeName>
            <Initials>JA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Methlie</LastName>
            <ForeName>Camilla Borthen</ForeName>
            <Initials>CB</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Addict Med</MedlineTA>
        <NlmUniqueID>101306759</NlmUniqueID>
        <ISSNLinking>1932-0620</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CoiStatement>The authors report no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>26</Day>
          <Hour>21</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34954745</ArticleId>
        <ArticleId IdType="doi">10.1097/ADM.0000000000000944</ArticleId>
        <ArticleId IdType="pii">01271255-900000000-98960</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
